Article
Oncology
Robert Haddad, Tanguy Y. Seiwert, Laura Q. M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Razvan Cristescu, Jonathan Cheng, Ranee Mehra
Summary: This study found that tumor mutational burden (TMB), neoantigen load (NL), and T-cell-inflamed gene expression profile (Tcell(inf)GEP) were associated with response, and inflammatory biomarkers (Tcell(inf)GEP and PD-L1) showed a trend towards clinical response. The study also found concordance between HPV status detected by whole exome sequencing (WES) and p16 immunohistochemistry. These findings contribute to predicting response to anti-PD-1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Richard S. P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross
Summary: The study found low prevalence of non-amplification short variants (SV) mutations in CD274, with mutation types and rates varying by tumor type. Specific mutation types may affect the expression level of PD-L1 protein and potentially function as resistance biomarkers in ICPI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross
Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu
Summary: The expression of NKG2A and PD-L1 together can be used as a combinatorial biomarker to predict the therapeutic response to immune checkpoint blockade in patients with muscle-invasive bladder cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S. Lopez, Rachel H. Ng, Neena Leggett, Vanessa D. Jonsson, Jelani C. Zarif, Peter P. Lee, Xiuli Wang, Catalina Martinez, Tanya B. Dorff, Stephen J. Forman, Saul J. Priceman
Summary: This study reveals an alternative mechanism by which the combination of CAR T cells and immune checkpoint blockade modulates the immune landscape of solid tumors to enhance therapeutic efficacy of CAR T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Julie Lecuelle, Laure Favier, Clea Fraisse, Aurelie Lagrange, Coureche Kaderbhai, Romain Boidot, Sandy Chevrier, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Francois Ghiringhelli
Summary: In patients with non-small cell lung cancer (NSCLC), high expression of endogenous retroviruses (ERVs) was associated with better treatment efficacy and immune response. This study found that high MER4 ERV expression was associated with improved progression-free survival (PFS) and overall survival (OS) in NSCLC patients receiving immune checkpoint inhibitors (ICI). Additionally, adding MER4 to existing transcriptomic signatures improved the predictive power for response to ICI.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Congkuan Song, Zhiquan Wu, Qingwen Wang, Yujin Wang, Zixin Guo, Sheng Li, Weidong Hu
Summary: A study identified two genes that can predict response to immunotherapy in lung adenocarcinoma patients, developed a signature to distinguish high- and low-risk patients, and constructed a nomogram by combining immune prognostic signature with clinical features.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Valentin Vautrot, Hafidha Bentayeb, Sebastien Causse, Carmen Garrido, Jessica Gobbo
Summary: Immunotherapy, particularly through the blockade of immune checkpoints such as PD-1/PD-L1, has become increasingly important in cancer treatment by reactivating the immune system to fight cancer cells. However, resistance to these treatments in a certain proportion of patients has led to efforts to combine PD-1/PD-L1 immunotherapy with targeting other immune checkpoints to improve outcomes. Exosomes, small vesicles secreted by various cells including tumor cells, play a key role in mediating immune resistance and establishing metastatic niches. Research on specific exosomal proteins like PD-L1, CTLA-4, TIM-3, CD73/39, LAG-3, and TIGIT aims to enhance understanding of tumor resistance mechanisms and guide therapeutic decisions in immunotherapy.
Review
Oncology
Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou Huang, Mohammad Reza Karimzadeh, Amir Abaas Momtazi-Borojeni, Sheng Chen
Summary: Exosomes, specifically those derived from cancer cells, contain immunosuppressive proteins such as PD-L1, which can hinder immune responses and promote tumor progression. Blocking the interaction between PD-1 and PD-L1 can enhance the efficacy of cancer treatment by restoring anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Medicine, General & Internal
Qiu-Xia Liu, Jian-Guo Wei, Yi-Yi Chen, Jian-Fang Wang
Summary: This study investigated the effective treatment options for patients with squamous cell lung cancer who have both EGFR mutations and PD-L1 over-expression. The results suggest that ICI monotherapy could be an effective treatment choice, but close monitoring of immune-related adverse events is necessary.
Article
Oncology
Naoyuki Okabe, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Satoshi Muto, Yuki Matsumura, Yutaka Shio, Hiroyuki Suzuki
Summary: Pulmonary large cell carcinoma (LCC) is a poorly defined entity among non-small cell lung cancers (NSCLCs) with no effective anticancer drugs, but the development of immune checkpoint inhibitors (ICIs) has changed the therapeutic strategies. This case report presents a successful treatment of LCC with pembrolizumab, suggesting that immunotherapy targeting PD-1/PD-L1 may be important for patients with PD-L1 positive LCC.
Article
Oncology
Yangyang Zhang, Lingxiu Zeng, Meng Wang, Zhenwei Yang, Hailin Zhang, Liping Gao, Ranran Zhang, Jialong Liu, Wenqing Shan, Ying Chang, Lan Liu, Qiu Zhao, Yong Li, Jing Liu
Summary: The study found that RIG-I plays an important role in the immunotherapy of colon cancer by maintaining the stability of PD-L1 to promote immune evasion. Silencing RIG-I increases the sensitivity of tumor cells to T cell killing and slows down the growth of colon tumors. High expression of RIG-I promotes tumor progression and enhances the sensitivity to PD-1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Xisha Chen, Kuansong Wang, Shilong Jiang, Hongyin Sun, Xuanling Che, Minghui Zhang, Jiaying He, Ying Wen, Mengting Liao, Xiangling Li, Xiaoming Zhou, Jianxun Song, Xingcong Ren, Wenjun Yi, Jinming Yang, Xiang Chen, Mingzhu Yin, Yan Cheng
Summary: Our study reveals that eEF2K is correlated with therapeutic response and prognosis in melanoma patients treated with anti-PD-1 therapy. We also show that eEF2K plays a vital role in regulating the tumor immune microenvironment by controlling PD-L1 expression. In addition, combining eEF2K inhibition with ICB therapy may provide a potential combination therapeutic strategy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Fu-xue Huang, Jun-wan Wu, Xia-qin Cheng, Jiu-hong Wang, Xi-zhi Wen, Jing-jing Li, Qiong Zhang, Hang Jiang, Qiu-yue Ding, Xiao-feng Zhu, Xiao-shi Zhang, Ya Ding, Dan-dan Li
Summary: This study showed that high expression of HHLA2 is associated with better prognosis and improved response to immune checkpoint blockades in melanoma patients. The expression of HHLA2 is also positively correlated with the density of CD8(+) tumor infiltrating lymphocytes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Scott A. Foster, Daniel M. Whalen, Aysxeguel Oezen, Matthew J. Wongchenko, JianPing Yin, Ivana Yen, Gabriele Schaefer, John D. Mayfield, Juliann Chmielecki, Philip J. Stephens, Lee A. Albacker, Yibing Yan, Kyung Song, Georgia Hatzivassiliou, Charles Eigenbrot, Christine Yu, Andrey S. Shaw, Gerard Manning, Nicholas J. Skelton, Sarah G. Hymowitz, Shiva Malek
Article
Oncology
James H. Suh, Adrienne Johnson, Lee Albacker, Kai Wang, Juliann Chmielecki, Garrett Frampton, Laurie Gay, Julia A. Elvin, Jo-Anne Vergilio, Siraj Ali, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross
Article
Oncology
Sai-Hong Ignatius Ou, Jean Cui, Alexa B. Schrock, Michael E. Goldberg, Viola W. Zhu, Lee Albacker, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali
Article
Genetics & Heredity
Ryan J. Hartmaier, Jehad Charo, David Fabrizio, Michael E. Goldberg, Lee A. Albacker, William Pao, Juliann Chmielecki
Article
Biology
Floris Foijer, Lee A. Albacker, Bjorn Bakker, Diana C. Spierings, Ying Yue, Stephanie Z. Xie, Stephanie Davis, Annegret Lutum-Jehle, Darin Takemoto, Brian Hare, Brinley Furey, Roderick T. Bronson, Peter M. Lansdorp, Allan Bradley, Peter K. Sorger
Article
Allergy
Hye Young Kim, Ya-Jen Chang, Srividya Subramanian, Hyun-Hee Lee, Lee A. Albacker, Ponpan Matangkasombut, Paul B. Savage, Andrew N. J. McKenzie, Dirk E. Smith, James B. Rottman, Rosemarie H. DeKruyff, Dale T. Umetsu
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2012)
Article
Immunology
Lee A. Albacker, Piia Karisola, Ya-Jen Chang, Sarah E. Umetsu, Meixia Zhou, Omid Akbari, Norimoto Kobayashi, Nicole Baumgarth, Gordon J. Freeman, Dale T. Umetsu, Rosemarie H. DeKruyff
JOURNAL OF IMMUNOLOGY
(2010)
Article
Immunology
L. A. Albacker, S. Yu, D. Bedoret, W-L Lee, S. E. Umetsu, S. Monahan, G. J. Freeman, D. T. Umetsu, R. H. DeKruyff
MUCOSAL IMMUNOLOGY
(2013)
Article
Immunology
Ya-Jen Chang, Hye Young Kim, Lee A. Albacker, Nicole Baumgarth, Andrew N. J. McKenzie, Dirk E. Smith, Rosemarie H. DeKruyff, Dale T. Umetsu
Article
Biochemistry & Molecular Biology
Lee A. Albacker, Vinod Chaudhary, Ya-Jen Chang, Hye Young Kim, Ya-Ting Chuang, Muriel Pichavant, Rosemarie H. DeKruyff, Paul B. Savage, Dale T. Umetsu
Article
Chemistry, Organic
Vinod Chaudhary, Lee A. Albacker, Shenglou Deng, Ya-Ting Chuang, Yubo Li, Dale T. Umetsu, Paul B. Savage
Article
Oncology
Ryan J. Hartmaier, Lee A. Albacker, Juliann Chmielecki, Mark Bailey, Jie He, Michael E. Goldberg, Shakti Ramkissoon, James Suh, Julia A. Elvin, Samuel Chiacchia, Garrett M. Frampton, Jeffrey S. Ross, Vincent Miller, Philip J. Stephens, Doron Lipson
Article
Immunology
ME Keir, SC Liang, I Guleria, YE Latchman, A Qipo, LA Albacker, M Koulmanda, GJ Freeman, MH Sayegh, AH Sharpe
JOURNAL OF EXPERIMENTAL MEDICINE
(2006)